(Q42711983)

5 November 2017

Fatal infusion reactions to cetuximab: role of immunoglobulin e-mediated anaphylaxis (English)

1 reference

5 November 2017

1 reference

1 reference

5

Thomas A E Platts-Mills

1 reference

5 November 2017

2

Scott P Commins

1 reference

5 November 2017

Yoann Pointreau

1

1 reference

5 November 2017

Gilles Calais

series ordinal

3

1 reference

5 November 2017

Hervé Watier

series ordinal

4

1 reference

5 November 2017

language of work or name

English

0 references

publication date

12 December 2011

1 reference

Journal of Clinical Oncology

5 November 2017

1 reference

5 November 2017

30

1 reference

5 November 2017

3

1 reference

5 November 2017

334; author reply 335

1 reference

Anti-cetuximab IgE ELISA for identification of patients at a high risk of cetuximab-induced anaphylaxis

5 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4908455

The relevance of tick bites to the production of IgE antibodies to the mammalian oligosaccharide galactose-α-1,3-galactose

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4908455

Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4908455

Structure-function relationships of the variable domains of monoclonal antibodies approved for cancer treatment

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4908455

2nd Charles Richet et Jules Héricourt workshop: therapeutic antibodies and anaphylaxis; May 31-June 1, 2011, Tours, France

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4908455

Managing cetuximab hypersensitivity-infusion reactions: incidence, risk factors, prevention, and retreatment

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4908455

High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history

16 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22162592

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Fatal Infusion Reaction to Cetuximab: The Need for Predictive Risk Factors and Safer Patient Selection

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22162592

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1200/JCO.2011.38.4701

1 reference

5 November 2017

1 reference

5 November 2017

PubMed publication ID

22162592

1 reference